Trial · NCT02908685
Participant flow210
How many started, completed or left each group, period by period.
1 to 20 of 210
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 Placebo-Controlled | STARTED | Part 1 Group A Cohort 1: Adolescents and Adults (3 mg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group A Cohort 2: Adolescents and Adults (5 mg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group A Cohort 1: Adolescents and Adults (Placebo) | 3 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group A Cohort 2: Adolescents and Adults (Placebo) | 3 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B Cohort 1: Children (Placebo) | 3 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B Cohort 2: Children (Placebo) | 4 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B Cohort 3: Children (Placebo) | 3 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group A: OLE | 0 | |
| Part 1 Placebo-Controlled | STARTED | Part 1 Group B: OLE | 0 | |
| Part 1 Placebo-Controlled | STARTED | Part 2: Risdiplam | 0 | |
| Part 1 Placebo-Controlled | STARTED | Part 2: Placebo | 0 | |
| Part 1 Placebo-Controlled | COMPLETED | Part 1 Group A Cohort 1: Adolescents and Adults (3 mg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | COMPLETED | Part 1 Group A Cohort 2: Adolescents and Adults (5 mg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | COMPLETED | Part 1 Group A Cohort 1: Adolescents and Adults (Placebo) | 3 | |
| Part 1 Placebo-Controlled | COMPLETED | Part 1 Group A Cohort 2: Adolescents and Adults (Placebo) | 3 | |
| Part 1 Placebo-Controlled | COMPLETED | Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam) | 7 | |
| Part 1 Placebo-Controlled | COMPLETED | Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam) | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02908685/flow